In cancers with high LY6K expression that were difficult to treat, such as cervical, pancreatic, ovarian, head and neck, lung, stomach, and triple-negative breast cancer, inhibition of LY6K expression through small-molecule binding can be used to inhibit the growth of cancer cells (Newell et al., 2020). The gene discussed is LY6K; the disease is triple-negative breast carcinoma.